• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

僵人综合征及相关疾病的诊断、发病机制与治疗。

Stiff-person syndrome and related disorders - diagnosis, mechanisms and therapies.

机构信息

Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA.

Neuroimmunology Unit, National and Kapodistrian University of Athens Medical School, Athens, Greece.

出版信息

Nat Rev Neurol. 2024 Oct;20(10):587-601. doi: 10.1038/s41582-024-01012-3. Epub 2024 Sep 3.

DOI:10.1038/s41582-024-01012-3
PMID:39227464
Abstract

Stiff-person syndrome (SPS) is the prototypical and most common autoimmune neuronal hyperexcitability disorder. It presents with stiffness in the limbs and axial muscles, stiff gait with uncontrolled falls, and episodic painful muscle spasms triggered by anxiety, task-specific phobias and startle responses, collectively leading to disability. Increased awareness of SPS among patients and physicians has created concerns about diagnosis, misdiagnosis and treatment. This Review addresses the evolving diagnostic challenges in SPS and overlapping glutamic acid decarboxylase (GAD) antibody spectrum disorders, highlighting the growing number of overdiagnoses and focusing on the progress made in our understanding of SPS pathophysiology, antibodies against GAD and other inhibitory synaptic antigens, and the fundamentals of neuronal hyperexcitability. It considers the role of impaired GABAergic or glycinergic inhibition in the cortex and at multiple levels in the neuraxis; the underlying autoimmunity and involvement of GAD antibodies; immunopathogenic mechanisms beyond antibodies, including environmental triggers; familial and immunogenetic susceptibility; and potential T cell cytotoxicity. Finally, the mechanistic rationale for target-specific therapeutic interventions is presented along with the available therapeutic approaches, including enhancers of GABA signalling drugs and immunotherapies.

摘要

僵人综合征(SPS)是典型且最常见的自身免疫性神经元过度兴奋疾病。其特征为四肢和脊柱肌肉僵硬、步态僵硬且无法控制、伴有焦虑、特定恐惧症和惊吓反应的阵发性疼痛性肌肉痉挛,从而导致残疾。患者和医生对 SPS 的认识不断提高,引起了对其诊断、误诊和治疗的关注。本综述讨论了 SPS 及重叠的谷氨酸脱羧酶(GAD)抗体谱疾病的不断变化的诊断挑战,重点介绍了日益增多的过度诊断,并关注了 SPS 病理生理学、针对 GAD 及其他抑制性突触抗原的抗体、以及神经元过度兴奋的基本原理方面的研究进展。本文考虑了皮层和神经轴内多个水平 GABA 能或甘氨酸能抑制受损的作用;潜在的自身免疫和 GAD 抗体的参与;抗体以外的免疫发病机制,包括环境触发因素;家族和免疫遗传易感性;以及潜在的 T 细胞细胞毒性。最后,提出了针对特定治疗靶点的治疗干预的机制原理,以及现有的治疗方法,包括 GABA 信号增强药物和免疫疗法。

相似文献

1
Stiff-person syndrome and related disorders - diagnosis, mechanisms and therapies.僵人综合征及相关疾病的诊断、发病机制与治疗。
Nat Rev Neurol. 2024 Oct;20(10):587-601. doi: 10.1038/s41582-024-01012-3. Epub 2024 Sep 3.
2
Stiff Person Syndrome and GAD Antibody-Spectrum Disorders.僵人综合征和 GAD 抗体谱障碍。
Continuum (Minneap Minn). 2024 Aug 1;30(4):1110-1135. doi: 10.1212/CON.0000000000001457.
3
Stiff person syndrome.僵人综合征。
Handb Clin Neurol. 2024;203:211-233. doi: 10.1016/B978-0-323-90820-7.00003-3.
4
Therapies in Stiff-Person Syndrome: Advances and Future Prospects Based on Disease Pathophysiology.僵人综合征的治疗:基于疾病病理生理学的进展和未来前景。
Neurol Neuroimmunol Neuroinflamm. 2023 Apr 14;10(3). doi: 10.1212/NXI.0000000000200109. Print 2023 May.
5
[Stiff-Person Syndrome and Related Autoantibodies].[僵人综合征及相关自身抗体]
Brain Nerve. 2018 Apr;70(4):357-362. doi: 10.11477/mf.1416201008.
6
[Stiff-person syndrome and related autoantibodies].[僵人综合征及相关自身抗体]
Brain Nerve. 2013 Apr;65(4):395-400.
7
Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes.自身免疫性僵硬人综合征及相关脊髓病:电生理和免疫学过程的理解。
Muscle Nerve. 2012 May;45(5):623-34. doi: 10.1002/mus.23234.
8
Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies.僵人综合征和 GABA 能神经元兴奋性、免疫发病机制及抗体治疗更新:广泛性焦虑症抗体谱障碍。
Neurotherapeutics. 2022 Apr;19(3):832-847. doi: 10.1007/s13311-022-01188-w. Epub 2022 Jan 27.
9
The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome.抗谷氨酸脱羧酶(GAD)抗体阳性僵人综合征患者的临床谱
Neurology. 2000 Nov 28;55(10):1531-5. doi: 10.1212/wnl.55.10.1531.
10
Stiff-person syndromes: motor cortex hyperexcitability correlates with anti-GAD autoimmunity.僵人综合征:运动皮层兴奋性过高与抗谷氨酸脱羧酶自身免疫相关。
Neurology. 2004 Apr 27;62(8):1357-62. doi: 10.1212/01.wnl.0000120543.65812.33.

引用本文的文献

1
CAR T-cells meet autoimmune neurological diseases: a new dawn for therapy.嵌合抗原受体T细胞与自身免疫性神经疾病:治疗的新曙光
Front Immunol. 2025 Jul 18;16:1604174. doi: 10.3389/fimmu.2025.1604174. eCollection 2025.
2
[Treatment of neuroimmunological diseases with chimeric antigen receptor (CAR) T cells : Experience and new developments].嵌合抗原受体(CAR)T细胞治疗神经免疫性疾病:经验与新进展
Z Rheumatol. 2025 Jul 10. doi: 10.1007/s00393-025-01676-2.
3
An Adult Case of Diabetes With High Levels of GAD Antibodies Without Insulin Deficiency for More Than 10 Years.

本文引用的文献

1
Stiff Person Syndrome and GAD Antibody-Spectrum Disorders.僵人综合征和 GAD 抗体谱障碍。
Continuum (Minneap Minn). 2024 Aug 1;30(4):1110-1135. doi: 10.1212/CON.0000000000001457.
2
Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome.抗 CD19 CAR T 细胞在严重治疗抵抗性僵人综合征中的成功应用。
Proc Natl Acad Sci U S A. 2024 Jun 25;121(26):e2403227121. doi: 10.1073/pnas.2403227121. Epub 2024 Jun 17.
3
Successful Autologous Hematopoietic Stem Cell Transplant in Glycine Receptor Antibody-Positive Stiff Person Syndrome: A Case Report.
1例成年糖尿病患者,谷氨酸脱羧酶抗体水平高且无胰岛素缺乏超过10年。
Case Rep Endocrinol. 2025 Feb 27;2025:9712659. doi: 10.1155/crie/9712659. eCollection 2025.
4
Ketamine for acute management of refractory stiff person syndrome: a case report.氯胺酮用于难治性僵人综合征的急性处理:一例报告
BMC Neurol. 2025 Apr 9;25(1):149. doi: 10.1186/s12883-025-04157-w.
5
Immunogenetic Studies in Patients With GAD-Positive Stiff-Person Syndrome Reveal Novel Lymphocytic Genes and -Gene Variants.GAD 阳性僵人综合征患者的免疫遗传学研究揭示了新的淋巴细胞基因和基因变体。
Neurol Neuroimmunol Neuroinflamm. 2025 Mar;12(2):e200373. doi: 10.1212/NXI.0000000000200373. Epub 2025 Feb 11.
6
Ten Years of ® : Decade in Review.十年的®:十年回顾。
Neurol Neuroimmunol Neuroinflamm. 2025 Jan;12(1):e200363. doi: 10.1212/NXI.0000000000200363. Epub 2024 Dec 26.
成功进行甘氨酸受体抗体阳性僵人综合征的自体造血干细胞移植:病例报告。
Neurol Neuroimmunol Neuroinflamm. 2024 Mar;11(2):e200197. doi: 10.1212/NXI.0000000000200197. Epub 2024 Jan 3.
4
Severe Stiff-Person Syndrome After COVID: The First Video-Documented COVID Exacerbation and Viral Implications.新冠后严重僵人综合征:首例视频记录的新冠恶化及病毒学意义
Neurol Neuroimmunol Neuroinflamm. 2024 Mar;11(2):e200192. doi: 10.1212/NXI.0000000000200192. Epub 2023 Dec 26.
5
Stiff Person Spectrum Disorders-An Update and Outlook on Clinical, Pathophysiological and Treatment Perspectives.僵人谱系障碍——临床、病理生理及治疗前景的最新进展与展望
Biomedicines. 2023 Sep 10;11(9):2500. doi: 10.3390/biomedicines11092500.
6
Prevalence, Clinical Profiles, and Prognosis of Stiff-Person Syndrome in a Japanese Nationwide Survey.日本全国性调查中的僵人综合征的患病率、临床特征和预后。
Neurol Neuroimmunol Neuroinflamm. 2023 Sep 22;10(6). doi: 10.1212/NXI.0000000000200165. Print 2023 Nov.
7
Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome.依氟鸟氨酸治疗重症肌无力之外:FcRn 靶向治疗在僵人综合征中的作用。
J Neurol. 2024 Jan;271(1):254-262. doi: 10.1007/s00415-023-11970-1. Epub 2023 Sep 8.
8
Stiff person spectrum disorder diagnosis, misdiagnosis, and suggested diagnostic criteria.僵人综合征的诊断、误诊和建议的诊断标准。
Ann Clin Transl Neurol. 2023 Jul;10(7):1083-1094. doi: 10.1002/acn3.51791. Epub 2023 May 22.
9
Glycine Receptor Antibody-Associated Progressive Encephalomyelitis with Rigidity and Myoclonus (PERM) During SARS-CoV-2 Infection: a Video-Case Report.新型冠状病毒感染期间与甘氨酸受体抗体相关的进行性脑脊髓炎伴强直和肌阵挛(PERM):一例视频病例报告
Mov Disord Clin Pract. 2023 Mar 16;10(5):824-826. doi: 10.1002/mdc3.13712. eCollection 2023 May.
10
Therapies in Stiff-Person Syndrome: Advances and Future Prospects Based on Disease Pathophysiology.僵人综合征的治疗:基于疾病病理生理学的进展和未来前景。
Neurol Neuroimmunol Neuroinflamm. 2023 Apr 14;10(3). doi: 10.1212/NXI.0000000000200109. Print 2023 May.